Applications for LCRF—Daiichi Sankyo—AstraZeneca Research Grant on Antibody Drug Conjugates
The mission of the Lung Cancer Research Foundation is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.
To advance this mission, the foundation collaborates with Daiichi Sankyo and AstraZeneca to fund innovative projects focused on antibody-drug conjugates (ADCs) to improve outcomes for people with lung cancer. The grants program will provide $270,000 over a period of two years for projects focused on one or more of the following topics that support research studies to develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs, including: employment of state-of-the art technology to characterize ADC target expression on patient biopsies; development and evaluation of patient-derived xenograft models (PDX) from patients responsive and/or resistant to TROP2 directed or HER2 directed ADCs; discovery and/or validation of predictive biomarkers of TROP2 directed or HER2 directed ADCs efficacy in the lung cancer; prevalence of potential prognostic or predictive biomarkers from lung cancer cells and/or blood; co-expression of the identified biomarkers with other known biomarkers (eg actionable drivers, immune-related biomarkers, poor prognosis biomarkers); and evolution of the biomarkers pre-, during- and post-SOC treatment.
The program will provide grants of up to $135,000 annually over two years. Senior investigators with more than 10 years of experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than 10 years of experience in other disease areas or topics.
To be eligible, investigators must be affiliated with a nonprofit academic or research institution and be post-doctoral researchers, clinical fellows, or mid-career investigators with less than ten years of experience since their initial faculty appointment. Applicants from United States-based and international institutions are eligible to apply and may hold any residency/citizenship status.
For complete program guidelines and application instructions, see the Lung Cancer Research Foundation website.
Submissions to this sponsor/donor are managed by the Office of Corporate and Foundation Relations. Please contact your unit-assigned ASUF Director of Development or Research Advancement Specialist at your earliest convenience to ensure ASU's strategic coordination and management of funding applications.